Antithrombin in sepsis revisited
Copyright policy )Antithrombin in sepsis revisited
As the pivotal phase III randomized controlled clinical trial on antithrombin concentrate in patients with severe sepsis did not show a beneficial effect of antithrombin treatment on 28-day mortality, the interest in the potential use of this treatment modality in sepsis has diminished. However, recent data on the effect of antithrombin administration on coagulation in combination with recent analyses from the clinical trials that were aimed to restore physiological anticoagulant pathways in patients with sepsis may revitalize the interest in antithrombin concentrate for the treatment of severe sepsis.
- Amsterdam UMC Netherlands
- UNIVERSITEIT VAN AMSTERDAM Netherlands
- Academic Medical Center - University of Amsterdam Netherlands
- University of Amsterdam Netherlands
- Amsterdam UMC, location AMC Netherlands
Fibrin Fibrinogen Degradation Products, Treatment Outcome, Critical Care, Critical Illness, Sepsis, Commentary, Anticoagulants, Humans, Antithrombins
Fibrin Fibrinogen Degradation Products, Treatment Outcome, Critical Care, Critical Illness, Sepsis, Commentary, Anticoagulants, Humans, Antithrombins
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).24 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!